Logo image of SLNO

SOLENO THERAPEUTICS INC (SLNO) Stock Fundamental Analysis

NASDAQ:SLNO - Nasdaq - US8342033094 - Common Stock - Currency: USD

82.63  -1.15 (-1.37%)

After market: 82.63 0 (0%)

Fundamental Rating

2

Overall SLNO gets a fundamental rating of 2 out of 10. We evaluated SLNO against 555 industry peers in the Biotechnology industry. While SLNO seems to be doing ok healthwise, there are quite some concerns on its profitability. SLNO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year SLNO has reported negative net income.
SLNO had a negative operating cash flow in the past year.
In the past 5 years SLNO always reported negative net income.
In the past 5 years SLNO always reported negative operating cash flow.
SLNO Yearly Net Income VS EBIT VS OCF VS FCFSLNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -62.58%, SLNO is doing worse than 60.54% of the companies in the same industry.
SLNO's Return On Equity of -85.78% is in line compared to the rest of the industry. SLNO outperforms 49.73% of its industry peers.
Industry RankSector Rank
ROA -62.58%
ROE -85.78%
ROIC N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.69%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
SLNO Yearly ROA, ROE, ROICSLNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLNO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLNO Yearly Profit, Operating, Gross MarginsSLNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, SLNO has more shares outstanding
The number of shares outstanding for SLNO has been increased compared to 5 years ago.
The debt/assets ratio for SLNO is higher compared to a year ago.
SLNO Yearly Shares OutstandingSLNO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SLNO Yearly Total Debt VS Total AssetsSLNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

SLNO has an Altman-Z score of 25.79. This indicates that SLNO is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 25.79, SLNO belongs to the top of the industry, outperforming 95.14% of the companies in the same industry.
SLNO has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
SLNO's Debt to Equity ratio of 0.22 is on the low side compared to the rest of the industry. SLNO is outperformed by 70.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Altman-Z 25.79
ROIC/WACCN/A
WACCN/A
SLNO Yearly LT Debt VS Equity VS FCFSLNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 19.31 indicates that SLNO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 19.31, SLNO belongs to the top of the industry, outperforming 92.61% of the companies in the same industry.
A Quick Ratio of 19.31 indicates that SLNO has no problem at all paying its short term obligations.
SLNO's Quick ratio of 19.31 is amongst the best of the industry. SLNO outperforms 92.61% of its industry peers.
Industry RankSector Rank
Current Ratio 19.31
Quick Ratio 19.31
SLNO Yearly Current Assets VS Current LiabilitesSLNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

1

3. Growth

3.1 Past

SLNO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -72.39%.
EPS 1Y (TTM)-72.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

SLNO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 47.10% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y22.76%
EPS Next 2Y50.45%
EPS Next 3Y47.1%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLNO Yearly Revenue VS EstimatesSLNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2025 2026 2027 100M 200M 300M 400M 500M
SLNO Yearly EPS VS EstimatesSLNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50 -100 -150

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SLNO. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 73.65 indicates a quite expensive valuation of SLNO.
88.47% of the companies in the same industry are more expensive than SLNO, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of SLNO to the average of the S&P500 Index (21.70), we can say SLNO is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 73.65
SLNO Price Earnings VS Forward Price EarningsSLNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLNO Per share dataSLNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SLNO does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as SLNO's earnings are expected to grow with 47.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.45%
EPS Next 3Y47.1%

0

5. Dividend

5.1 Amount

No dividends for SLNO!.
Industry RankSector Rank
Dividend Yield N/A

SOLENO THERAPEUTICS INC

NASDAQ:SLNO (7/1/2025, 9:08:31 PM)

After market: 82.63 0 (0%)

82.63

-1.15 (-1.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners107.29%
Inst Owner Change7.52%
Ins Owners1.46%
Ins Owner Change-10.09%
Market Cap4.16B
Analysts86.67
Price Target109.82 (32.91%)
Short Float %8.57%
Short Ratio4.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.19%
Min EPS beat(2)-7.96%
Max EPS beat(2)-0.42%
EPS beat(4)1
Avg EPS beat(4)-47.06%
Min EPS beat(4)-186.49%
Max EPS beat(4)6.6%
EPS beat(8)2
Avg EPS beat(8)-40.15%
EPS beat(12)5
Avg EPS beat(12)-24.27%
EPS beat(16)7
Avg EPS beat(16)-16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2%
PT rev (3m)45.06%
EPS NQ rev (1m)-18.5%
EPS NQ rev (3m)-22.22%
EPS NY rev (1m)-8.77%
EPS NY rev (3m)-17.51%
Revenue NQ rev (1m)0.68%
Revenue NQ rev (3m)34.3%
Revenue NY rev (1m)5.1%
Revenue NY rev (3m)25.68%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 73.65
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 17.95
P/tB 18.45
EV/EBITDA N/A
EPS(TTM)-4.62
EYN/A
EPS(NY)1.12
Fwd EY1.36%
FCF(TTM)-1.77
FCFYN/A
OCF(TTM)-1.77
OCFYN/A
SpS0
BVpS4.6
TBVpS4.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.58%
ROE -85.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.69%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.31
Quick Ratio 19.31
Altman-Z 25.79
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)3.86%
Cap/Depr(5y)2.62%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-72.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.02%
EPS Next Y22.76%
EPS Next 2Y50.45%
EPS Next 3Y47.1%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-275.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-321.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-320.8%
OCF growth 3YN/A
OCF growth 5YN/A